In contrast to KLF5 acetylation in epidermal cells and prostate cancer cells, acetylation of Klf5 in ESCs only enhances its transcriptional activity, rather than switching from a transcriptional repressor to an activator. This evidence concerns the gene KLF5 and prostate carcinoma.